Bioconversion of lovastatin to a novel statin by Amycolatopsis sp.

Applied Microbiology and Biotechnology

Volumn 79, Issue 2, 2008, Pages 209-216

  Zhuge, Bin ^a   Fang, Hui Ying ^a   Yu, Hai ^a   Rao, Zhi Ming ^a   Shen, Wei ^a   Song, Jian ^a   Zhuge, Jian ^a  

^a JIANGNAN UNIVERSITY   (China)

Author keywords

Amycolatopsis sp.; HMG CoA reductase; Structure; Wuxistatin

Indexed keywords

AMYCOLATOPSIS; HMG-COA REDUCTASE; WUXISTATIN;

BIOCONVERSION; CELL CULTURE; CHEMICAL MODIFICATION; MORPHOLOGY; RNA; STOICHIOMETRY;

COENZYMES;

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; BUTYRIC ACID; HYDROXYL GROUP; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; RNA 16S; STATINE DERIVATIVE; UNCLASSIFIED DRUG; WUXISTATIN;

BACTERIUM; CHEMOTAXONOMY; ENZYME ACTIVITY; INHIBITION; IONIZATION; MORPHOLOGY;

AMYCOLATOPSIS; ANIMAL EXPERIMENT; ARTICLE; BIOTRANSFORMATION; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMOTAXONOMY; CHOLESTEROL SYNTHESIS; CHROMATOGRAPHY; DRUG DOSE INCREASE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME MECHANISM; FUNGAL STRAIN; FUNGUS; GENE SEQUENCE; IC 50; MORPHOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTON NUCLEAR MAGNETIC RESONANCE; PURIFICATION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ACTINOMYCETALES; BUTYRATES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; RNA, RIBOSOMAL, 16S;

AMYCOLATOPSIS; AMYCOLATOPSIS SP.;

EID: 42549083828     PISSN: 01757598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00253-008-1430-5     Document Type: Article

References (38)

1. Alberts AW (1990) Lovastatin and simvastatin-inhibitors of HMG CoA reductase and cholesterol biosynthesis. Cardiology 77:14-21
2. Anderson JF, Tatsuta K, Gunji H, Ishiyama T, Hutchinson CR (1993) Substrate specificity of 6-deoxyerythronolide B hydroxylase, a bacterial cytochrome P450 of erythromycin A biosynthesis. Biochemistry 32:1905-1913
3. Batal HA, Krantz MJ, Dale RA, Mehler PS, Steiner JF (2007) Impact of prescription size on statin adherence and cholesterol levels. BMC Health Serv Res 7:175
4. Berger S, Braun S (2004) 200 and more NMR experiments: a practical course. Wiley-VCH, Weinhei
5. Bousquet P, Gayet JL (2003) Pharmacologic characteristics of rosuvastatin, a new HMG-CoA reductase inhibitor. Therapie 58:113-121
6. Chapman MJ, McTaggart F (2002) Optimizing the pharmacology of statins: characteristics of rosuvastatin. Atheroscler Suppl 2:33-36
7. Davidson MH (2002) Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drug 11:125-141
8. Edwards PA, Lemongello D, Fogelman AM (1979) Improved methods for the solubilization and assay of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Lipid Res 20:40-46
9. Endo A, Kuroda M, Tsujita Y (1976) ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo) 29:1346-1348
10. Ferris MJ (1990) Process for the preparation of 6-alpha-hydroxymethyl lovastatin derivatives. European Patent Application A1 0381478
11. Frost FJ, Petersen H, Tollestrup K, Skipper B (2007) Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 131:950-951
12. Gunde-Cimerman N, Plemenitas A, Cimerman A (1993) Pleurotus fungi produce mevinolin, an inhibitor of HGM CoA reductase. FEMS Microbiol Lett 133:333-338
13. Hajjaj H, Niederberger P, Duboc P (2001) Lovastatin biosynthesis by Aspergillus terreus in a chemically defined medium. Appl Environ Microbiol 67:2596-2602
14. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Asano T, Hayakawa M (2004) 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res 10:8648-8655
15. Ishida W, Kajiwara T, Ishii M, Fujiwara F, Taneichi H, Takebe N, Takahashi K, Kaneko Y, Segawa I, Inoue H, Satoh J (2007) Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J Exp Med 212:265-73
16. Istvan E (2003) Statin inhibition of HMG-CoA reductase: a 3-dimensional view. Atheroscler Suppl l4:3-8
17. Istvan ES, Deisenhofer J (2007) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292:1160-1164
18. Jekkel A, Kónya A, Ilkóy E, Boros S, Horváth G, Sütó J (1997) Microbial conversion of mevinolin. J Antibiot 50:750-754
19. Joshua H, Schwartz MS, Wilson KE (1991) L-669, 262, a potent HMG-CoA reductase inhibitor. J Antibiot 44:366-370
20. Kim B, Sahin N, Tan GY, Zakrzewska-Czerwinska J, Goodfellow M (2002) Amycolatopsis eurytherma sp. nov., a thermophilic actinomycete isolated from soil. Int J Syst Evol Microbiol 52:889-894
21. Kodach LL, Bleuming SA, Peppelenbosch MP, Hommes DW, van den Brink GR, Hardwick JC (2007) The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. Gastroenterology 133:1272-1281
22. Lorke DA (1983) New approach to practical acute toxicity testing. Arch Toxicol 54:275-287
23. Manzoni M, Rollini M (2002) Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl Microbiol Biotechnol 58(5):555-64
24. Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, Combe C, Rayner HC, Saito A, Gillespie BW, Young EW (2005) HMG-coenzyme A reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 45:119-26
25. Mendes MV, Anton N, Martin JF, Aparicio JF (2005) Characterization of the polyene macrolide P450 epoxidase from Streptomyces natalensis that converts de-epoxypimaricin into pimaricin. Biochem J 386:57-62
26. Miyadoh S, Hamada M, Hotta K, Kudo T, Seino A, Vobis G, Yokota A (1997) Atlas of Actinomycetes. Asakura, Tokyo
27. Park EJ, Lee D, Shin YG, Lantvit DD, van Breemen RB, Kinghorn AD, Pezzuto JM (2001) Analysis of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors using liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl 754:327-332
28. Park JW, Lee JK, Kwon TJ, Yi DH, Kim YJ, Moon SH, Suh HH, Kang SM, Park YI (2003) Bioconversion of compactin into pravastatin by Streptomyces sp. Biotechnol Lett 25:1827-1831
29. Parker RA, Clark RW, Sit SY, Lanier TL, Grosso RA, Wright JJ (1990) Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors. J Lipid Res 31(7):1271-1282
30. Peng Y, Demain AL (2000) Bioconversion of compactin to pravastatin by Actinomadura sp. ATCC 55678. J Mol Catal B Enzym 10:151-156
31. Rainey FA, Ward-Rainey N, Kroppenstedt RM, Stackebrandt E (1996) The genus Nocardiopsis represents a phylogenetically coherent taxon and a distinct actinomycete lineage: proposal of Nocardiopsaceae fam. nov. Int J Syst Bacteriol 46:1088-1092
32. Rosenson RS (2003) Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther 1:495-505
33. Song H, Guo T, Zhang Y, Mi H, Zhang Q (1999) Studies on pharmacognostic identification and quality control standards for hongqu. Zhongguo Zhong Yao Za Zhi 24(5):262-265
34. Terahara, Tanaka, Minoru (1985) Process for preparing 3-hydroxy-ML-236B derivatives known as M-4 and M-4′. US Patent 4,537,859
35. sca gene from Streptomyces carbophilus by ML-236B sodium salt and phenobarbital. Gene 210:109-116
36. Watanabe I, Nara F, Serizawa N (1995) Cloning, characterization and expression of the gene encoding cytochrome P-450sca-2 from Streptomyces carbophilus involved in the production of pravastatin, a specific HMG-CoA reductase inhibitor. Gene 163:81-85
37. Williamson JM (1989) HMG-CoA reductase inhibitor produced by Nocardia sp.(MA6455). European Patent A20337548
38. Zhuge J, Fang HY, Yu H. (2004) Amycolatosis and biological conversion of lovastatin into wuxistatin thereby. Chinese Patent Zl 200410044893.6